Zobrazeno 1 - 9
of 9
pro vyhledávání: '"J. G. Tibben"'
Autor:
E.B. Koenders, Roland A. M. J. Claessens, Frans H.M. Corstens, Otto C. Boerman, J. G. Tibben, K. Y. Pak, Leon F.A.G. Massuger, George F. Borm
Publikováno v:
Nuclear Medicine and Biology. 21:17-24
A new 99m Tc labelling method using a cleavable chelator, RP-1, was developed. In this study Balb/c mice with ovarian carcinoma xenografts received various Fab′ fragments labelled with 99m Tc either directly or via RP-1. Kidney uptake was significa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc0d8adc36a3704493996e63b4161df3
https://doi.org/10.1016/0969-8051(94)90125-2
https://doi.org/10.1016/0969-8051(94)90125-2
Autor:
F.H.M. Corstens, C.P.T. Schijf, E.B. Koenders, O.C. Boerman, W.C.A.M. Buijs, Jeffry A. Siegel, Leon F.A.G. Massuger, J. G. Tibben, Carla F. M. Molthoff
Publikováno v:
European Journal of Nuclear Medicine, 25, pp. 1552-1561
European Journal of Nuclear Medicine, 25, 1552-1561
European Journal of Nuclear Medicine, 25, 1552-1561
In this study the potential of intraperitoneal (i.p.) and intravenous (i.v.) administration of chimeric iodine-131-labelled MOv18 IgG for radioimmunotherapy was determined. The dosimetry associated with both routes of administration of cMOv18 IgG was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96f2c14dc89bd520935d40058634e3d6
https://pubmed.ncbi.nlm.nih.gov/9799353
https://pubmed.ncbi.nlm.nih.gov/9799353
Publikováno v:
International journal of cancer. 66(4)
The bispecific monoclonal antibody (biMAb) OC/TR combines the anti-ovarian-cancer reactivity of the MOv18 monoclonal antibody (MAb) with the reactivity of an anti-CD3 MAb. Pre-clinical studies have indicated that this biMAb is able to redirect the cy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f541240eb81db72d78d4994abea79761
https://pubmed.ncbi.nlm.nih.gov/8635863
https://pubmed.ncbi.nlm.nih.gov/8635863
Publikováno v:
Anticancer research. 15(5B)
The anti-tumour x anti-T-cell bispecific monoclonal antibody (biMAb) OC/TR is a biologically produced biMAb combining the anti-ovarian carcinoma activity of the MOv18 MAb with anti-CD3/T-cell receptor (TCR) complex activity. In this study, the in vit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ccba2bd342ea880a13f688a0d87474c0
https://pubmed.ncbi.nlm.nih.gov/8572619
https://pubmed.ncbi.nlm.nih.gov/8572619
Autor:
C. M. G. Thomas, F.H.M. Corstens, J. G. Tibben, Leon F.A.G. Massuger, M.F.G. Segers, C. P. T. Schijf, O.C. Boerman
Publikováno v:
Nuclear Medicine Communications, 16, pp. 853-859
Nuclear Medicine Communications, 16, 853-859
Nuclear Medicine Communications, 16, 853-859
The human anti-mouse antibody (HAMA) response was determined in the serum of patients suspected of having ovarian cancer who underwent radioimmunoscintigraphy with either 99 Tc m -OV-TL 3 Fab' In = 20) or 111 In-DTPA-OV-TL 3 F(ab') 2 (n = 73). Blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5481e0619ad8715731a75ddb18520c4a
https://hdl.handle.net/2066/22221
https://hdl.handle.net/2066/22221
Autor:
Roland A. M. J. Claessens, J. G. Tibben, George F. Borm, F.H.M. Corstens, O.C. Boerman, Leon F.A.G. Massuger
Publikováno v:
European journal of nuclear medicine. 21(11)
The effect of the route administration on the distribution of radioiodinated OV-TL 3 F(ab′)2 was studied in Balb/c female mice with intraperitoneal or subcutaneous ovarian carcinoma xenografts. In the intraperitoneal tumour model in which both asci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22f4840d9e1d2533b7d0f8af2407e3eb
https://pubmed.ncbi.nlm.nih.gov/7859769
https://pubmed.ncbi.nlm.nih.gov/7859769
Autor:
K. Y. Pak, Leon F.A.G. Massuger, P. Kenemans, S. P. Strijk, Roland A. M. J. Claessens, F.H.M. Corstens, J. G. Tibben, C. P. T. Schijf
Publikováno v:
Nuclear medicine communications. 13(12)
Fab' fragments of the monoclonal antibody OV-TL 3, that recognizes an ovarian carcinoma-associated antigen (OA3), were labelled with 99Tcm using D-glucarate as a ligand. Twenty patients suspected of having primary or recurrent ovarian cancer received
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1505c1488c7cefea7018f941e3a934bf
https://pubmed.ncbi.nlm.nih.gov/1465272
https://pubmed.ncbi.nlm.nih.gov/1465272
Publikováno v:
European journal of gynaecological oncology. 13(4)
An unselected group of 30 patients with advanced epithelial ovarian cancer, FIGO stage IIb-IV, was treated with cyclophosphamide (750 mg/m2) and cisplatin (75 mg/m2) both administered intravenously on a single day at a 3-weeks interval (CP). At a med
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2fd9f52134e916df20ce61e4088a039b
https://pubmed.ncbi.nlm.nih.gov/1516584
https://pubmed.ncbi.nlm.nih.gov/1516584
Autor:
K. G. G. Keijser, J.W.M. van der Meer, M. van Deuren, J. G. Tibben, O.C. Boerman, F.H.M. Corstens, P.H.M. de Mulder, Roland A. M. J. Claessens, Leon F.A.G. Massuger
Publikováno v:
JNCI Journal of the National Cancer Institute. 85:1003-1004
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bccb0bbf2875e80edf461af0a0129b56
https://doi.org/10.1093/jnci/85.12.1003
https://doi.org/10.1093/jnci/85.12.1003